Peripheral Blood Transcriptome Heterogeneity and Prognostic Potential in Lung Cancer Revealed by RNA-Seq

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2021 Jul 21

PMID 34288383

Citations 4

Authors

Qi Zhang

Manchao Kuang

Haiyin An

Yajing Zhang

Kai Zhang

Lin Feng

Lei Zhang

Shujun Cheng

Affiliations

Soon will be listed here.

Abstract

Understanding of the complex interaction between the peripheral immune system and lung cancer (LC) remains incomplete, limiting patient benefit. Here, we aimed to characterize the host peripheral immune response to LC and investigate its potential prognostic value. Bulk RNA-sequencing data of peripheral blood leucocytes (PBLs) from healthy volunteers and LC patients (n = 142) were analysed for characterization of host systemic immunity in LC. We observed broad blood transcriptome perturbations in LC patients that were heterogeneous, as two new subtypes were established independent of histology. Functionally, the heterogeneity between the two subtypes included dysregulation of diverse biological processes, such as the cell cycle, blood coagulation and inflammatory signalling pathways, together with the abundance and activity of blood cells, particularly lymphocytes and neutrophils, ultimately manifesting as differences in antitumour immune status. Based on these findings, a prognostic model composed of ten genes dysregulated in one LC subtype with relatively poor immune status was developed and validated in a Gene Expression Omnibus (GEO) data set (n = 108), helping to generate a prognostic nomogram. Collectively, our study provides novel and comprehensive insight into the heterogeneity of the host peripheral immune response to LC. The expression heterogeneity-based predictive model may help guide prognostic management for LC patients.

Citing Articles

Assessing the potential relevance of CEACAM6 as a blood transcriptional biomarker.

Rinchai D, Chaussabel D F1000Res. 2024; 11():1294.

PMID: 39239252 PMC: 11375406. DOI: 10.12688/f1000research.126721.2.

Increased expression of individual genes in whole blood is associated with late-stage lung cancer at and close to diagnosis.

Urbarova I, Skogholt A, Sun Y, Mai X, Gronberg B, Sandanger T Sci Rep. 2023; 13(1):20760.

PMID: 38007577 PMC: 10676373. DOI: 10.1038/s41598-023-48216-z.

Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer.

celesnik H, Potocnik U Cancers (Basel). 2022; 14(3).

PMID: 35158858 PMC: 8833511. DOI: 10.3390/cancers14030591.

Peripheral blood transcriptome heterogeneity and prognostic potential in lung cancer revealed by RNA-Seq.

Zhang Q, Kuang M, An H, Zhang Y, Zhang K, Feng L J Cell Mol Med. 2021; 25(17):8271-8284.

PMID: 34288383 PMC: 8419186. DOI: 10.1111/jcmm.16773.

References

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

Saffari A, Arno M, Nasser E, Ronald A, Wong C, Schalkwyk L . RNA sequencing of identical twins discordant for autism reveals blood-based signatures implicating immune and transcriptional dysregulation. Mol Autism. 2019; 10:38. PMC: 6839145. DOI: 10.1186/s13229-019-0285-1. View

Budhu S, Schaer D, Li Y, Toledo-Crow R, Panageas K, Yang X . Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal. 2017; 10(494). PMC: 5851440. DOI: 10.1126/scisignal.aak9702. View

Bathgate R, Halls M, van der Westhuizen E, Callander G, Kocan M, Summers R . Relaxin family peptides and their receptors. Physiol Rev. 2013; 93(1):405-80. DOI: 10.1152/physrev.00001.2012. View

Li B, Cui Y, Diehn M, Li R . Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017; 3(11):1529-1537. PMC: 5710196. DOI: 10.1001/jamaoncol.2017.1609. View

Altorki N, Markowitz G, Gao D, Port J, Saxena A, Stiles B . The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2018; 19(1):9-31. PMC: 6749995. DOI: 10.1038/s41568-018-0081-9. View

Song L, Ma S, Chen L, Miao L, Tao M, Liu H . Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer. Cancer Sci. 2019; 110(7):2100-2109. PMC: 6609818. DOI: 10.1111/cas.14068. View

Ming W, Xie H, Hu Z, Chen Y, Zhu Y, Bai Y . Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis. Front Oncol. 2019; 9:985. PMC: 6779774. DOI: 10.3389/fonc.2019.00985. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

10.

Rami-Porta R, Asamura H, Travis W, Rusch V . Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):138-155. DOI: 10.3322/caac.21390. View

11.

Chiossone L, Dumas P, Vienne M, Vivier E . Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018; 18(11):671-688. DOI: 10.1038/s41577-018-0061-z. View

12.

Dumeaux V, Fjukstad B, Fjosne H, Frantzen J, Holmen M, Rodegerdts E . Interactions between the tumor and the blood systemic response of breast cancer patients. PLoS Comput Biol. 2017; 13(9):e1005680. PMC: 5619688. DOI: 10.1371/journal.pcbi.1005680. View

13.

Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q . Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med. 2018; 24(7):978-985. DOI: 10.1038/s41591-018-0045-3. View

14.

Karasaki T, Nagayama K, Kuwano H, Nitadori J, Sato M, Anraku M . An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. J Thorac Oncol. 2017; 12(5):791-803. DOI: 10.1016/j.jtho.2017.01.005. View

15.

Zhang Q, Kuang M, An H, Zhang Y, Zhang K, Feng L . Peripheral blood transcriptome heterogeneity and prognostic potential in lung cancer revealed by RNA-Seq. J Cell Mol Med. 2021; 25(17):8271-8284. PMC: 8419186. DOI: 10.1111/jcmm.16773. View

16.

Zhang L, Peng R, Sun Y, Wang J, Chong X, Zhang Z . Identification of key genes in non-small cell lung cancer by bioinformatics analysis. PeerJ. 2019; 7:e8215. PMC: 6911687. DOI: 10.7717/peerj.8215. View

17.

Shi L, Li K, Guo Y, Banerjee A, Wang Q, Lorenz U . Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A. 2018; 115(46):11808-11813. PMC: 6243255. DOI: 10.1073/pnas.1804931115. View

18.

Sadasivam S, DeCaprio J . The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer. 2013; 13(8):585-95. PMC: 3986830. DOI: 10.1038/nrc3556. View

19.

Palumbo J, Kombrinck K, Drew A, Grimes T, Kiser J, Degen J . Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000; 96(10):3302-9. View

20.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View